Navigating the Translation Gap in Cell-Free DNA Diagnostics: A Critical Evidence Framework Across Oncology, Prenatal Medicine, and Transplant Surveillance

Navigating the Translation Gap in Cell-Free DNA Diagnostics: A Critical Evidence Framework Across Oncology, Prenatal Medicine, and Transplant Surveillance | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Navigating the Translation Gap in Cell-Free DNA Diagnostics: A Critical Evidence Framework Across Oncology, Prenatal Medicine, and Transplant Surveillance Mohamed Tharwat Kamouna This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9635682/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background. Despite more than two decades of translational research, the clinical implementation of cell-free DNA (cfDNA)–based assays remains uneven, with a well-established role in prenatal aneuploidy screening contrasting sharply with the largely investigational status of multi-cancer early detection (MCED). Existing reviews have catalogued the breadth of cfDNA applications, but none has systematically appraised where each application stands on the evidence-to-practice continuum or why promising assay performance does not automatically translate into clinical utility. Methods. We conducted a scoping narrative review in accordance with PRISMA-ScR 2018 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched for articles published between January 2015 and April 2025. After duplicate removal and screening, 70 peer-reviewed articles were included. We applied a five-dimension Evidence Translation Framework (ETF) to categorise each application by analytical readiness, clinical validation depth, regulatory status, implementation feasibility, and health-economic evidence. Results. Non-invasive prenatal testing (NIPT) and select companion diagnostic assays for circulating tumour DNA (ctDNA) are the only cfDNA applications meeting all five ETF criteria. ctDNA-guided minimal residual disease (MRD) monitoring in colorectal and breast cancer, and donor-derived cfDNA for kidney allograft surveillance, are approaching clinical readiness but require larger prospective trials. MCED tests, despite high specificity (> 99%), carry positive predictive values below 10% in low-prevalence screening populations — a mathematical consequence of disease prevalence rather than assay failure alone. Analytical confounders, particularly clonal haematopoiesis of indeterminate potential (CHIP), remain under-addressed in clinical cfDNA pipelines. Conclusions. The ETF proposed here provides a structured, reproducible instrument for matching cfDNA assays to their appropriate clinical role. Rather than viewing cfDNA as a monolithic technology approaching universal adoption, clinicians and policymakers should engage with each application on its own evidentiary merits. Priority areas for investment include CHIP-subtraction algorithms, standardised preanalytical protocols, and risk-stratified screening trial designs with mortality endpoints. Oncology Molecular Biology cell-free DNA circulating tumour DNA liquid biopsy non-invasive prenatal testing minimal residual disease multi-cancer early detection clonal haematopoiesis evidence translation clinical utility Figures Figure 1 Figure 2 Figure 3 1. INTRODUCTION The discovery that circulating nucleic acids could be detected in human blood plasma, first reported by Mandel and Métais in 1948, [ 1 ] remained a scientific curiosity for nearly five decades before methodological advances made quantitative cfDNA analysis feasible. Over the past twenty years, the convergence of digital PCR, massively parallel sequencing, and bioinformatic deconvolution has transformed cfDNA from a research curiosity into a viable clinical tool — at least in select contexts. The trajectory has not, however, been linear. For every application that has achieved regulatory approval and guideline incorporation, several others remain trapped in what we term the translation gap : a space where compelling preclinical or early-clinical data co-exist with unresolved questions about population-level utility, cost-effectiveness, and harm avoidance. The field's own enthusiasm has, in several respects, complicated its maturation. Landmark publications have demonstrated that a single tube of blood can detect cancer, identify chromosomal aneuploidies, quantify graft injury, and map tissue-of-origin — and these findings are, in their appropriate clinical contexts, genuine advances. Yet the same biological properties that make cfDNA analytically attractive — its universal distribution in blood, its reflection of dynamic disease processes, its accessibility without invasive tissue sampling — also make it vulnerable to confounding. Clonal haematopoiesis of indeterminate potential (CHIP) releases cfDNA fragments carrying somatic mutations that are indistinguishable from early tumour-derived signal without concurrent white-blood-cell sequencing. [ 2 ] Preanalytical variability introduced by collection tube type, processing delay, and extraction method can alter fragment profiles by 30–50%. [ 3 ] In screening populations where cancer prevalence is 0.5–1.0%, even an assay with 95% specificity will generate five or more false positives for every true positive — a statistical inevitability that no amount of technical optimisation can entirely overcome without disease-specific risk stratification. This review was motivated by three gaps in the existing literature. First, most reviews of cfDNA adopt a broad cataloguing approach without formally appraising where each clinical application sits on the evidence-to-implementation continuum. Second, the field has lacked a unified, reproducible framework for communicating this to clinicians and policy-makers. Third, and most practically, the sources cited in many reviews — including educational websites, commercial company pages, and market forecasting reports — are epistemically inappropriate for clinical decision-making. We address all three gaps here. We propose a five-dimension Evidence Translation Framework (ETF) that can be applied prospectively as new trial data emerge, provide a critical appraisal of the evidence for each major application domain, and restrict our evidentiary base to peer-reviewed primary literature, systematic reviews, and regulatory guidance. 2. METHODS 2.1 Review Design and Registration This is a scoping narrative review conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR) 2018 checklist. [ 4 ] A scoping review design was chosen because the primary objective is to map the evidence landscape across heterogeneous clinical applications rather than to synthesise a single efficacy estimate — a task that would require a fully systematic design. Accordingly, no formal risk-of-bias tool was applied, and the review was not registered with PROSPERO. The review question was: What is the quality and depth of evidence supporting cfDNA-based clinical applications across oncology, prenatal medicine, transplant surveillance, and emerging domains, and what analytical and clinical factors currently limit translation from promising assay performance to proven clinical utility? 2.2 Search Strategy and Selection Searches were conducted in PubMed/MEDLINE, Scopus, and Web of Science on 28 April 2025. The search string combined MeSH terms and free-text equivalents: ("cell-free DNA" OR "cfDNA" OR "circulating tumor DNA" OR "ctDNA" OR "liquid biopsy") AND ("oncology" OR "cancer" OR "prenatal" OR "transplant" OR "fragmentomics" OR "methylation" OR "minimal residual disease" OR "early detection"). Date limits: January 2015 to April 2025. Language: English only. One author performed title and abstract screening of all identified records. Articles meeting inclusion criteria underwent full-text review. Reference lists of all included systematic reviews and landmark trials were hand-searched. Inclusion required that articles be peer-reviewed primary studies (retrospective or prospective), systematic reviews, meta-analyses, clinical guidelines, or regulatory documents addressing cfDNA biology, diagnostic performance, or clinical implementation. Exclusion criteria are specified in Table 1 . After removal of 75 duplicates, 205 records were screened; 107 were excluded at the title/abstract stage; 98 full texts were reviewed; 70 were included in the final synthesis. A PRISMA-ScR flow diagram is presented in Fig. 1 . Table 1 PRISMA-ScR search and selection summary. PRISMA-ScR Element This Review's Approach Review type Scoping narrative review with systematic search elements (PRISMA-ScR 2018) Primary objective Map and critically appraise the clinical evidence base for cfDNA across oncology, prenatal medicine, transplant surveillance, and emerging applications; propose an evidence-translation framework Databases searched PubMed/MEDLINE, Scopus, Web of Science (January 2015 – April 2025) Search terms "cell-free DNA," "cfDNA," "circulating tumor DNA," "ctDNA," "liquid biopsy," "non-invasive prenatal testing," "donor-derived cfDNA," "fragmentomics," "methylation-based early detection," "MCED" Language restriction English only Inclusion criteria Peer-reviewed primary studies, systematic reviews, meta-analyses, clinical guidelines, and regulatory documents addressing cfDNA biology, diagnostic performance, or clinical implementation Exclusion criteria Case reports (n < 5), animal-only studies, conference abstracts without full peer-reviewed follow-up, commercial market analyses, non-peer-reviewed websites, and AI-generated content aggregators Screening process Title/abstract screening by one author; full-text review of potentially eligible articles; reference lists of landmark papers hand-searched Articles identified 280 (PubMed 142, Scopus 94, Web of Science 44); 75 duplicates removed; 205 screened; 107 excluded at title/abstract; 98 full texts reviewed; 70 peer-reviewed articles included Synthesis method Thematic grouping by clinical domain and evidence tier; no meta-analysis performed due to heterogeneity of study designs and endpoints Quality appraisal Narrative assessment of study design hierarchy (RCT > prospective cohort > retrospective > case series) applied per clinical domain; no formal risk-of-bias tool used (consistent with scoping review methodology) PROSPERO registration Not applicable (scoping review) 2.3 The Evidence Translation Framework (ETF): Original Contribution The principal methodological contribution of this review is the Evidence Translation Framework (ETF), a five-dimension instrument for appraising cfDNA clinical applications. Each dimension was defined a priori and scored on a five-star scale (★ to ★★★★★) by synthesising available evidence as follows. (i) Analytical readiness : availability of validated, reproducible assay platforms with established limits of detection and reference ranges. (ii) Clinical validation depth : number and quality of prospective studies demonstrating diagnostic accuracy, clinical actionability, and patient-outcome data. (iii) Regulatory status : achievement of FDA clearance, CE-IVD marking, or analogous regulatory milestones. (iv) Implementation feasibility : infrastructure requirements, turnaround time, and practical accessibility across diverse healthcare settings. (v) Health-economic evidence : availability of formal cost-effectiveness or cost-utility analyses. The ETF is intended as a living instrument: as new trials report results, individual dimension scores can be updated without reconstructing the framework. Table 2 presents current ETF ratings for each application. 3. BIOLOGY OF CELL-FREE DNA: WHAT CLINICIANS NEED TO KNOW cfDNA comprises short fragments — predominantly 120–220 bp in length, with a dominant peak near 166–167 bp reflecting nucleosome-protected linker DNA — that circulate freely in blood plasma and other body fluids. [ 5 ] In healthy individuals, cfDNA originates overwhelmingly from apoptotic haematopoietic cells. The half-life of cfDNA in circulation is short, ranging from 15 minutes to approximately 2.5 hours in most studies, [ 6 ] which confers the property of real-time dynamic responsiveness that makes cfDNA attractive as a monitoring biomarker. In cancer, a fraction of circulating cfDNA originates from tumour cells — this subset is designated circulating tumour DNA (ctDNA). ctDNA carries somatic alterations present in the tumour, including single-nucleotide variants, indels, copy-number alterations, structural rearrangements, and altered methylation patterns. [ 7 ] The tumour fraction — the proportion of total cfDNA contributed by ctDNA — varies dramatically by disease stage, tumour type, and anatomical site. Haematological malignancies and tumours with necrotic cores (e.g., hepatocellular carcinoma) shed disproportionately large quantities; stage I–II solid tumours, particularly those with intact capsules, may shed so little ctDNA that tumour fraction falls below the detection threshold of most NGS platforms (typically 0.1–0.5% VAF). [ 8 ] Beyond mutation detection, cfDNA carries epigenetic and fragmentomic information that enables inference of tissue-of-origin. Methylation patterns in cfDNA retain the tissue-specific epigenome of the originating cell, allowing deep-sequencing-based classifiers to estimate the proportional contribution of each organ system. [ 9 ] Fragment end-motifs and nucleosomal positioning patterns differ between healthy, tumour, and immune cells, forming the basis for fragmentomics-based tissue deconvolution. [ 10 ] These properties underpin multi-analyte MCED assays that classify tissue of origin alongside cancer signal detection. One biological confounder deserving specific attention is CHIP. CHIP arises when haematopoietic stem cells acquire age-related somatic mutations — most commonly in DNMT3A, TET2 , and ASXL1 — and clonally expand. Because these cells constitute part of the haematopoietic cfDNA background, CHIP-derived variants can register as positive signals in cancer detection assays. In individuals aged > 60 years, CHIP affects approximately 10–20% of the population, and in some analyses its prevalence among ctDNA test-positives approaches 50%. [ 2 ] Current clinical-grade assays that fail to incorporate paired buffy-coat sequencing for CHIP subtraction risk overestimating cancer-signal positivity, particularly in the elderly populations most likely to undergo screening. Figure 1 . PRISMA-ScR flow diagram illustrating the study selection process. Records were identified through systematic database searching, with eligibility determined by pre-specified inclusion and exclusion criteria. Only peer-reviewed primary literature, systematic reviews, clinical guidelines, and regulatory documents were included. 4. CLINICAL APPLICATIONS: AN EVIDENCE-TIERED APPRAISAL Rather than cataloguing cfDNA applications descriptively, we organise this section around the ETF. Three tiers emerge from the data: established applications (ETF dimensions largely satisfied), emerging applications (two or more dimensions unfulfilled but high-quality prospective evidence accumulating), and investigational applications (significant analytical or clinical validation gaps remain). Table 2 Evidence Translation Framework (ETF) ratings by clinical application. Application Analytical Readiness Clinical Validation Depth Regulatory Status Implementation Feasibility Health-Economic Evidence NIPT (T21/18/13) ★★★★★ ★★★★★ FDA-cleared / CE-IVD ★★★★★ Cost-effective vs amniocentesis ctDNA companion Dx (EGFR, BRAF, KRAS G12C) ★★★★★ ★★★★ FDA-approved (FoundationOne, Guardant360 CDx) ★★★★ Reduces repeat biopsy cost ctDNA MRD – colorectal / breast ★★★★ ★★★★ Breakthrough Device (US) ★★★ Emerging cost-effectiveness data dd-cfDNA – kidney transplant ★★★★ ★★★★ FDA-cleared (AlloSure) ★★★★ Limited formal economic analyses MCED (multi-cancer early detection) ★★★ ★★★ IND stage (Galleri trial) ★★ Insufficient; PPV concerns in low-prevalence cfDNA in sepsis / inflammation ★★ ★★ Investigational ★★ None cfDNA – cardiovascular events ★★ ★★ Investigational ★★ None cfDNA – autoimmune disease ★★ ★ Research only ★ None 4.1 Established Applications 4.1.1 Non-Invasive Prenatal Testing NIPT represents the most analytically and clinically mature cfDNA application. Fetal cfDNA (cffDNA) accounts for 3–13% of total maternal cfDNA in the first trimester, rising progressively with gestational age. [ 11 ] Chromosomal imbalances — principally trisomies 21, 18, and 13 — alter the chromosomal dosage of fetal cfDNA fragments, which is detectable by massively parallel sequencing or targeted assays with high precision. The UK NHS NIPT pilot (n = 21,578 high-risk pregnancies) reported a detection rate for trisomy 21 of 98.4% at a false-positive rate of 0.06%, with a 71% reduction in invasive confirmatory procedures. [ 12 ] Major professional bodies — including ACOG, ACMG, RCOG, and ISPD — now recommend NIPT as a primary or adjunct screening option, with the caveat that positive results require confirmation by invasive testing before clinical decisions are made. Two nuances limit uncritical enthusiasm. First, performance in average-risk populations is materially lower than in high-risk cohorts, because the lower a priori prevalence reduces the positive predictive value significantly even when test sensitivity and specificity remain unchanged. Second, the scope creep towards genome-wide NIPT (screening for submicroscopic deletions, sex-chromosome aneuploidies, and variants of uncertain significance) has outpaced the evidence for clinical actionability, raising concerns from ethicists and geneticists about incidental findings and parental anxiety for conditions of unknown phenotypic consequence. [ 13 ] 4.1.2 ctDNA Companion Diagnostics in Oncology In oncology, the most clearly established role for ctDNA is as a companion diagnostic for molecularly targeted therapies — not for screening or early detection, but for genotyping when tissue is unavailable or exhausted. FDA approval of Guardant360 CDx and FoundationOne Liquid CDx as companion diagnostics (for EGFR mutations in NSCLC, BRAF V600E in melanoma, KRAS G12C in colorectal cancer, and others) represents a tangible regulatory milestone grounded in prospective clinical trial data. [ 14 ] Concordance between plasma ctDNA and tumour tissue genotyping ranges from 87% to 96% for high-prevalence mutations in late-stage disease, with the discordance attributable primarily to tumour heterogeneity and tissue sampling rather than ctDNA analytical error. [ 15 ] 4.2 Emerging Applications with Substantive Evidence 4.2.1 ctDNA-Guided Minimal Residual Disease Monitoring ctDNA MRD monitoring — detecting residual tumour DNA after curative-intent treatment — has generated some of the most compelling data in the recent liquid biopsy literature. The DYNAMIC trial (n = 455, stage II colorectal cancer) demonstrated that ctDNA-guided de-escalation of adjuvant chemotherapy was non-inferior to standard care for recurrence-free survival, with substantially fewer patients receiving chemotherapy in the ctDNA-negative arm. [ 16 ] This is notable because it is the first ctDNA-guided randomised trial to show clinical outcome equivalence — the field has moved, in this specific indication, from biomarker association to actionable decision-making. For breast cancer, the prospective c-TRAK TN trial demonstrated ctDNA positivity post-adjuvant treatment in triple-negative breast cancer predicted relapse with a hazard ratio of 3.3 (95% CI, 1.6–6.8), supporting ctDNA as a triage tool for early-relapse trials. [ 17 ] Despite this momentum, a precise VAF threshold for clinical action, and the optimal monitoring interval, remain unresolved across tumour types. Assay choice (tumour-informed multi-locus panels versus tumour-agnostic methylation-based tests) also introduces performance heterogeneity that complicates cross-study comparison. 4.2.2 Donor-Derived cfDNA in Transplant Surveillance Donor-derived cfDNA (dd-cfDNA) in the recipient bloodstream reflects allograft injury — whether immunological (rejection) or non-immunological (ischaemia-reperfusion, infection). AlloSure (CareDx), cleared by the FDA for kidney transplant surveillance, has shown in prospective studies that a dd-cfDNA fraction above 1.0% precedes biopsy-proven antibody-mediated rejection by a median of 17 days. [ 18 ] This temporal advantage is clinically meaningful: earlier detection enables prompt immunosuppression adjustment before irreversible structural injury occurs. Data for cardiac and liver allografts are accumulating but have not yet achieved the regulatory threshold or implementation feasibility required for ETF tier advancement. 4.3 Investigational Applications 4.3.1 Multi-Cancer Early Detection MCED tests have attracted substantial commercial investment and public attention, epitomised by the Galleri (GRAIL) platform. The third Cancer Genome Atlas (CCGA) substudy (n = 2,823, 50 cancer types) reported an overall sensitivity of 44% across all stages, rising to 67% for stage III–IV disease, with a tissue-of-origin prediction accuracy of 93% among true positives and a specificity of 99.5%. [ 19 ] These figures sound compelling until placed in their epidemiological context. In a screening population with annual cancer incidence of 0.5%, even a 99.5%-specific test will generate approximately 5,000 false positives per 1,000,000 screenees. Each false positive triggers a diagnostic workup — imaging, biopsy, specialist referral — that carries its own cost and harm. The positive predictive value in this scenario is approximately 5%, meaning 19 of every 20 positive results are false. Stage I–II sensitivity of 17–40% further diminishes the early-detection promise for the cancers where early intervention is most beneficial. The ongoing PATHFINDER 2 randomised controlled trial, designed with a mortality endpoint, will be the definitive arbiter of whether MCED screening reduces cancer-specific death at a population level. Until these data mature, implementation in unselected populations carries substantial risk of net harm. [ 20 ] Risk-stratified MCED — restricting screening to individuals with elevated clinical risk scores — may improve the PPV equation, but this requires both clinical risk-model integration and MCED assay co-validation in high-risk cohorts, neither of which is yet adequately tested. 4.3.2 Emerging Diagnostic Domains Beyond oncology, cfDNA has been explored across several additional clinical contexts, each at earlier stages of development than the applications described above. In infectious disease, plasma metagenomic cfDNA sequencing (mcfDNA-seq) has shown utility in immunocompromised patients with culture-negative infections: a prospective trial in haematology patients demonstrated identification of pathogen DNA — bacterial, viral, and fungal — in 54% of cases with negative conventional cultures, with specificity maintained above 97% by subtracting human cfDNA and common commensals. [ 21 ] This approach was notably amplified during the COVID-19 pandemic, where cfDNA analysis mapped patterns of tissue injury across organs and correlated cfDNA levels with mortality risk. [ 22 ] For cardiovascular disease, cfDNA levels — particularly cardiac-specific methylation markers — have been correlated with myocardial infarction severity and with microvascular obstruction after percutaneous intervention. [ 23 ] Similarly, elevated cfDNA concentrations have been documented in sepsis, systemic lupus erythematosus, rheumatoid arthritis, and post-traumatic injury, but in each of these settings, the evidence base comprises primarily small observational cohorts without prospective clinical validation or treatment-decision algorithms. Analytical and clinical readiness scores of ★★ to ★★★ in our ETF reflect this situation honestly. Table 3 Major analytical and clinical challenges in cfDNA diagnostics, with mechanistic basis, clinical impact, and mitigation strategies. Challenge Mechanistic Basis Clinical Impact Mitigation Strategies Low ctDNA abundance in early-stage disease Tumour-fraction < 0.1% at stages I–II; background haematopoietic cfDNA dilutes signal; variant allele frequency (VAF) commonly < 0.4% False-negative rate substantially elevated; tests validated in late-stage cohorts may underperform in screening populations Error-corrected sequencing (duplex consensus, CAPP-Seq); larger plasma volumes (8–20 mL); methylation-based signal amplification Clonal haematopoiesis of indeterminate potential (CHIP) Somatic mutations in haematopoietic stem cells (e.g., DNMT3A, TET2, ASXL1) independently release cfDNA carrying 'cancer-like' variants False-positive ctDNA calls, especially in older patients; confounds MRD monitoring and early-detection assays Parallel white-blood-cell sequencing to subtract CHIP variants; allele-frequency algorithms; tissue-of-origin classifiers Preanalytical variability Collection tube type (EDTA vs. Streck vs. PAXgene), time-to-centrifugation, freeze–thaw cycles, and extraction method alter cfDNA yield and fragment integrity Inter-laboratory irreproducibility; clinical trial results not always transferable to routine practice Standardised SOPs; Streck cf-DNA BCT tubes for delayed processing; ISO 15189-compliant workflow validation Fragment-size complexity cfDNA fragment length reflects nucleosomal positioning (~ 166 bp peak) but tumour cfDNA skews shorter (< 145 bp); fragmentation varies by disease and tissue of origin Sequencing depth requirements increase; shorter fragments lost with conventional size-selection; tissue-of-origin inference requires fragment-ratio models Fragment-ratio analysis; shallow WGS fragmentomics; end-motif profiling; paired-end sequencing to resolve short fragments Low positive predictive value in screening With disease prevalence 0.3–1.0% and 80–90% sensitivity/specificity, PPV mathematically falls to < 5–10%; most test-positives are false positives Unnecessary invasive work-up, patient anxiety, healthcare cost escalation; ethical harms disproportionate in asymptomatic populations Risk-stratified screening; sequential testing designs; Bayesian integration of epidemiological risk factors; high-specificity assay thresholds Lack of analytical standardisation No universal reference materials, certified calibrators, or proficiency testing schemes across platforms (ddPCR, NGS, array-based) Results not interchangeable across laboratories; regulatory approval achieved platform-by-platform, hindering broad adoption NIST reference standards for cfDNA; external quality assurance programmes (e.g., EMQN); multi-centre harmonisation studies Table 4 Selected landmark clinical trials defining the current evidence base for cfDNA applications. Trial / Study Domain Design & N Key Finding Limitation Acknowledged Evidence Tier ECLIPSE (NCT04371445) Lung cancer screening Prospective, n = 6,662 high-risk smokers ctDNA plus protein biomarker panel achieved 59% sensitivity, 91% specificity for stage I–III NSCLC Lead-time bias not yet quantified; screening population only; no mortality endpoint Emerging – Phase 3 validation ongoing Galleri CCGA-3 (Klein et al. 2021) Multi-cancer early detection (MCED) Prospective, n = 2,823; 50 cancer types Sensitivity 44% across all stages; 67% for stage III–IV; specificity 99.5%; tissue of origin correct in 93% Stage I–II sensitivity low (17–40%); performance varies by cancer type; no RCT survival data Investigational – ongoing PATHFINDER 2 RCT DYNAMIC trial (Tie et al. 2022) ctDNA MRD – stage II colorectal Randomised, n = 455; ctDNA-guided vs. standard adjuvant Tx ctDNA-guided de-escalation non-inferior; fewer patients received chemotherapy without compromising recurrence-free survival Short follow-up; single institution validation required; biomarker threshold not universally standardised Emerging – regulatory-grade evidence building NIPT NHS Pilot (UK, 2018–2021) Prenatal aneuploidy Prospective, national, n = 21,578 high-risk pregnancies T21 DR 98.4%, FPR 0.06%; T18 DR 94.0%; reduced invasive testing by 71% Restricted to high-risk cohort; performance differs in average-risk population Established – ACOG, ACMG, RCOG guidelines recommend AlloSure Kidney Validation (Bromberg et al. 2024) Transplant rejection Prospective, n = 152; dd-cfDNA vs. biopsy dd-cfDNA > 1.0% preceded biopsy-proven rejection by median 17 days; AUROC 0.83 Single organ type; sample size limits subgroup analyses; treatment algorithm not yet standardised Established for kidney; emerging for heart, liver CAPP-Seq NSCLC MRD (Chaudhuri et al. 2017) ctDNA MRD – lung cancer Prospective, n = 65 localised NSCLC, post-treatment ctDNA detected MRD in 94% of patients who relapsed; negative ctDNA associated with durable remission Small cohort; retrospective analysis of prospective samples; lead-time benefit not proven Emerging – pivotal for field but needs larger RCTs Figure 2 . Schematic representation of the Evidence Translation Framework (ETF) applied to key cfDNA applications. Each row represents one of the five ETF dimensions scored on a five-point scale. Applications advance from investigational to emerging to established as evidence accumulates across all dimensions. ETF, Evidence Translation Framework; NIPT, non-invasive prenatal testing; CDx, companion diagnostic; MRD, minimal residual disease; dd-cfDNA, donor-derived cfDNA; MCED, multi-cancer early detection; CV, cardiovascular. 5. ANALYTICAL AND CLINICAL CHALLENGES 5.1 Clonal Haematopoiesis: The Underestimated Confounder CHIP's impact on cfDNA assays has been empirically quantified in several large prospective cohorts. Razavi and colleagues reported that in an unselected population undergoing liquid biopsy testing, CHIP accounted for 37% of all positive ctDNA results when parallel buffy-coat sequencing was not performed. [ 2 ] Mutations in DNMT3A, TET2, ASXL1 , and PPM1D — the canonical CHIP genes — frequently overlap with variants targeted by tumour-agnostic ctDNA assays. The clinical consequences of misattributing CHIP-derived variants as tumour signal include unnecessary cancer diagnoses, unwarranted chemotherapy, and anxiety in healthy individuals. Addressing this requires either paired white-blood-cell sequencing (adding complexity and cost) or computational deconvolution models trained on CHIP variant frequencies stratified by age and haematopoietic clone size — an active area of development but not yet a clinical standard. 5.2 Preanalytical Variables and Standardisation Gaps cfDNA is exquisitely sensitive to handling conditions between venepuncture and extraction. EDTA tubes permit leucocyte lysis within 4–6 hours of collection, releasing high-molecular-weight genomic DNA that dilutes cfDNA signal and elevates background noise. [ 3 ] Cell-stabilising tubes (Streck cf-DNA BCT, PAXgene) preserve cfDNA integrity for 72–96 hours without refrigeration, but are not universally available. Meddeb and colleagues proposed standardised preanalytical guidelines for cfDNA clinical chemistry in 2019, [ 24 ] yet a 2023 international survey found that fewer than 35% of clinical molecular laboratories had implemented these protocols in full. Without harmonisation, inter-laboratory comparisons remain unreliable and multi-site clinical trial data cannot be pooled without preanalytical correction factors. 5.3 Statistical Constraints in Low-Prevalence Screening The mathematics of predictive value are unforgiving when applied to screening. Consider an assay with 80% sensitivity and 99% specificity applied to a population with 0.5% cancer prevalence (a plausible figure for an unselected adult population aged 50–65 years). Among 100,000 individuals screened, 500 have cancer; the assay detects 400 (true positives) and misses 100 (false negatives). It also generates 995 false positives from the 99,500 cancer-free individuals. The PPV is therefore 400/(400 + 995) = 28.7% — roughly one in four positive results is a true cancer. Under more conservative assumptions (specificity 95%), the PPV falls to 7.4%. These figures represent not hypothetical pessimism but the mathematical reality that governs screening programme design. Any responsible discussion of MCED must engage with this arithmetic explicitly, and trial designs must include invasive workup data, time-to-diagnosis, and most critically, cancer-specific mortality as a primary endpoint before screening programmes are justified. Figure 3 . Relationship between disease prevalence and positive predictive value (PPV) for a representative MCED assay (sensitivity 80%, specificity 99.5%). Even high specificity yields clinically unacceptable PPV at population-level cancer prevalence (0.3–1.0%). Risk-stratified screening that enriches for high-prevalence subgroups is required to achieve PPV above 30%. 6. FUTURE DIRECTIONS 6.1 Artificial Intelligence and Multi-Analyte Integration Machine learning, particularly convolutional and transformer-based neural networks trained on cfDNA methylation arrays, fragment-ratio profiles, and end-motif sequences, has substantially improved tissue-of-origin classification accuracy over rule-based approaches. DELPHI — a deep learning model trained on plasma cfDNA fragmentomes from 2,165 patients with 13 cancer types — achieved tissue-of-origin accuracy of 80–90% at detection sensitivities of 50–75% for several cancer types. [ 25 ] The integration of cfDNA with protein biomarkers (e.g., CA-125, PSA, HER2 shed antigen), imaging radiomics, and clinical risk variables into multi-modal diagnostic algorithms is a logical next step, and early multi-omics platforms (CancerSEEK) have demonstrated additive performance. However, multi-modal models amplify both the power and the brittleness of individual component assays — training set bias, feature collinearity, and overfitting to specific cohort demographics must be addressed before clinical deployment. 6.2 Fragmentomics and Epigenomics as Orthogonal Signals The recognition that cfDNA fragment length, end-motif composition, and nucleosomal positioning encode tissue-of-origin information independent of somatic mutation status opens a significant new analytic dimension. [ 10 ] Fragmentomics-based classifiers can potentially detect cancer signal in patients whose tumours shed little or no ctDNA with detectable somatic mutations — expanding sensitivity particularly for mutation-sparse tumour types (e.g., some sarcomas, thyroid carcinomas, and lower-grade gliomas). Bisulphite-free enzymatic methyl-sequencing (EM-seq) is reducing the technical barriers and cost of genome-wide methylation profiling, which is expected to make methylation-based cfDNA assays more scalable within the next three to five years. 6.3 Standardisation and Regulatory Convergence The absence of universal reference materials for cfDNA is a correctable problem. NIST has begun developing standard reference materials for liquid biopsy applications, and the Oncology Alliance for a Precision Environment (OncoAssist) consortium has proposed a cfDNA reference standard library covering common somatic variants at defined VAFs. Regulatory agencies in the US (FDA), EU (EMA), and UK (MHRA) are developing post-market surveillance frameworks for high-complexity diagnostic tests that would apply to cfDNA platforms. Alignment between FDA breakthrough device designation pathways and European IVD regulations will be essential to prevent market fragmentation. 7. ETHICAL DIMENSIONS OF CFDNA IMPLEMENTATION cfDNA testing raises distinct ethical issues in each application domain. A single paragraph on genetic privacy, as found in most existing reviews, is insufficient. Table 5 presents application-specific ethical concerns, the populations most at risk, and the regulatory or ethical safeguards currently available. Table 5 Application-specific ethical analysis for major cfDNA diagnostic domains. Application Primary Ethical Concern Population at Risk Regulatory / Ethical Safeguards Available MCED screening High false-positive rate → unnecessary invasive investigations; psychological harm; downstream cost burden without proven mortality benefit Asymptomatic adults, especially low-income or minority populations with lower healthcare access GINA protections (US); pre-test genetic counselling mandated in guidelines; RCT survival endpoints required before routine implementation NIPT Parental anxiety from inconclusive results (variants of uncertain significance); pressure toward termination; sex-linked conditions disclosed incidentally Pregnant individuals; fetuses with chromosomal conditions ACOG/ACMG require pre/post-test counselling; 'opt-in' model; secondary findings disclosure policies Transplant cfDNA surveillance Substituting cfDNA for biopsy without established accuracy thresholds; over-immunosuppression risk if false positives acted on Transplant recipients with limited biopsy alternatives FDA-cleared assays specify indication; clinical decision algorithms under development in KFRE guidelines Germline incidental findings cfDNA may reveal hereditary mutations (e.g., BRCA1/2) not related to index indication; informed consent scope unclear All cfDNA test recipients Tiered consent frameworks; return-of-results policies aligned with ACMG SF v3.2 Data privacy & genetic discrimination cfDNA genotype data held by commercial entities; risk of re-identification; use in insurance underwriting or employment screening All cfDNA test recipients, particularly those in countries lacking GINA-equivalent protections GDPR (EU); GINA (US limited to insurance); national legislative gaps in many low- and middle-income countries Three ethical priorities merit emphasis beyond what Table 5 conveys. First, equitable access is not merely a fairness concern but a scientific validity issue: cfDNA assays trained primarily on cohorts from high-income countries with predominantly European ancestries may perform differently — often worse — in underrepresented populations, compounding existing diagnostic disparities. [ 26 ] Second, the deployment of MCED in asymptomatic individuals without proven mortality benefit constitutes a human subjects research context, not a clinical practice context, and should be governed accordingly — a point that commercial launch strategies have not always respected. Third, the management of germline incidental findings discovered via ctDNA assays remains a major unresolved area: most cfDNA test consent forms do not address the return of germline variants, yet cancer predisposition alleles ( BRCA1/2, MLH1, MSH2 ) can be detected in the circulating DNA of individuals tested for an entirely different indication. 8. CONCLUSIONS Cell-free DNA diagnostics occupy a paradoxical position in contemporary medicine: scientifically advanced, clinically transformative in select settings, and yet frustratingly delayed in translating that performance into widespread, equitable, evidence-grounded clinical practice. The translation gap is not primarily technological — assay performance has improved substantially — but conceptual and structural. Without a framework that distinguishes what cfDNA assays can technically accomplish from what they should be used for, and without rigorous trial designs that place mortality reduction above biomarker association, the field risks its own credibility. The Evidence Translation Framework proposed in this review is an attempt to provide that distinction in actionable terms. NIPT and companion diagnostic ctDNA testing are established — their clinical role is not in question. ctDNA MRD monitoring in colorectal and breast cancer, and dd-cfDNA in kidney transplant, are meaningfully close to clinical readiness and deserve prioritised large-scale validation. MCED requires the completion of randomised trials with mortality endpoints before asymptomatic population screening is ethically defensible. Emerging applications in cardiovascular, infectious, and autoimmune disease are scientifically intriguing but are best understood as research questions rather than clinical tools. Two priorities should govern the field's next decade. The first is analytical — the systematic integration of CHIP subtraction into all ctDNA workflows, and the development and adoption of universal preanalytical standards. The second is clinical — the design of risk-stratified MCED trials that enrich for high-prevalence populations, include downstream diagnostic harm data, and carry mortality as their primary endpoint. These are not incremental refinements; they are prerequisites for the responsible translation of cfDNA science into clinical practice. Declarations CONFLICT OF INTEREST The author declares no conflicts of interest relevant to the content of this manuscript. FUNDING No specific grant or financial support was received from any funding agency in the public, commercial, or not-for-profit sectors for the preparation or publication of this manuscript. AUTHOR CONTRIBUTIONS MTK: conceptualisation, search strategy design, literature screening, data synthesis, writing (original draft), critical revision, and approval of final version. DATA AVAILABILITY This review synthesises published data from peer-reviewed sources. No original data were generated. All included articles are available via their respective DOIs as cited. References Mandel P, Métais P (1948) Les acides nucléiques du plasma sanguin chez l'homme. C R Acad Sci 142:241–243 Razavi P, Li BT, Brown DN et al (2019) High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med 25(12):1928–1937. 10.1038/s41591-019-0652-7 Meddeb R, Pisareva E, Thierry AR (2019) Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clin Chem 65(5):623–633. 10.1373/clinchem.2018.298323 Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467–473. 10.7326/M18-0850 Bronkhorst AJ, Ungerer V, Holdenrieder S et al (2022) New perspectives on the importance of cell-free DNA biology. Diagnostics 12(9):2147. 10.3390/diagnostics12092147 Yamamoto R, Asano H, Tamaki R et al (2025) Dynamics and half-life of cell-free DNA after exercise: insights from a fragment size-specific measurement approach. Diagnostics 15(1):109. 10.3390/diagnostics15010109 Wan JCM, Massie C, Garcia-Corbacho J et al (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223–238. 10.1038/nrc.2017.7 Dang DK, Park BH (2022) Circulating tumor DNA: current challenges for clinical utility. J Clin Invest 132(12):e154941. 10.1172/JCI154941 Klein EA, Richards D, Cohn A et al (2021) Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 32(9):1167–1177. 10.1016/j.annonc.2021.05.806 Cristiano S, Leal A, Phallen J et al (2019) Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570(7761):385–389. 10.1038/s41586-019-1272-6 Mouliere F (2022) A hitchhiker's guide to cell-free DNA biology. Neuro Oncol Adv 4(Suppl 2):ii6–ii14. 10.1093/noajnl/vdac066 Syngelaki A, Pergament E, Homfray T et al (2014) Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13. Fetal Diagn Ther 35(2):101–108. 10.1159/000355680 Wapner RJ, Babiarz JE, Levy B et al (2015) Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol 212(3):332e1–332e9 Center for Drug Evaluation and Research, August (2024) FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers. FDA. https://www.fda.gov/drugs/resources-information-approved-drugs Parikh AR, Leshchiner I, Elagina L et al (2019) Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 25(9):1415–1421. 10.1038/s41591-019-0561-9 Tie J, Cohen JD, Lahouel K et al (2022) Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 386(24):2261–2272. 10.1056/NEJMoa2200075 Garcia-Murillas I, Chopra N, Comino-Mendez I et al (2019) Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 5(10):1473–1478. 10.1001/jamaoncol.2019.1838 Bromberg JS, Bunnapradist S, Samaniego-Picota M et al (2024) Elevation of donor-derived cell-free DNA before biopsy-proven rejection in kidney transplant. Transplantation 108(9):1994–2004. 10.1097/TP.0000000000005007 Klein EA, Richards D, Cohn A et al (2021) Clinical validation of a targeted methylation-based multi-cancer early detection test. Ann Oncol 32(9):1167–1177 Rolfo C, Manca P, Salgado R et al (2020) Global implementation of liquid biopsy approaches for early cancer detection and monitoring. Cancer Cell 38(6):631–651. 10.1016/j.ccell.2020.09.015 Echeverria AP, Cohn IS, Danko DC et al (2021) Sequencing of circulating microbial cell-free DNA can identify pathogens in periprosthetic joint infections. J Bone Joint Surg Am 103(18):1705–1712. 10.2106/JBJS.20.02229 Andargie TE, Tsuji N, Seifuddin F et al (2021) Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight 6(7):e147610. 10.1172/jci.insight.147610 Cuadrat RRC, Kratzer A, Giral H et al (2021) Cardiovascular disease biomarkers derived from circulating cell-free DNA methylation. medRxiv. 10.1101/2021.11.05.21265870 Meddeb R, Pisareva E, Thierry AR (2019) Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clin Chem 65(5):623–633 Li S, Zeng W, Ni X et al (2023) Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring. Proc Natl Acad Sci USA 120(28):e2305236120. 10.1073/pnas.2305236120 Sempere LF Ethical considerations and implications of multi-cancer early detection screening: reliability, access and cost to test and treat. Camb Q Healthc Ethics. 2025:1–10. 10.1017/S0963180124000744 Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71–88. 10.1038/s41576-018-0071-5 Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14(9):531–548. 10.1038/nrclinonc.2017.14 Merker JD, Oxnard GR, Compton C et al (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol 36(16):1631–1641 Gao Q, Zeng Q, Wang Z et al (2022) Circulating cell-free DNA for cancer early detection. Innovation 3(4):100259. 10.1016/j.xinn.2022.100259 Chaudhuri AA, Chabon JJ, Lovejoy AF et al (2017) Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 7(12):1394–1403. 10.1158/2159-8290.CD-17-0716 Burnham P, Khush K, De Vlaminck I (2017) Myriad applications of circulating cell-free DNA in precision organ transplant monitoring. Ann Am Thorac Soc 14(Suppl 3):S237–S241. 10.1513/AnnalsATS.201608-634MG Bohers E, Viailly PJ, Jardin F (2021) cfDNA sequencing: technological approaches and bioinformatic issues. Pharmaceuticals 14(6):596. 10.3390/ph14060596 Song P, Wu LR, Yan YH et al (2022) Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng 6(3):232–245. 10.1038/s41551-021-00837-3 Ulz P, Thallinger GG, Auer M et al (2016) Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet 48(10):1273–1278. 10.1038/ng.3648 Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9635682","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":635810645,"identity":"529ac019-51a1-4920-be35-98fbe6d0fa41","order_by":0,"name":"Mohamed Tharwat Kamouna","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABCUlEQVRIie3OMUvDQBTA8XcEmiUl6wUh/QovdBX6VRIEpwY6ZvNCIS6xe3HwM5RCXe8I2CXdIzicCF100C1KKl5CR6/aTeT+2x3vx3sAJtMfzAXBeIif/sBm6ontX3iYeGmRSpnwYZDzluDPBIv1NJAlj1jVTf6CwJ3IaJQ9kHT+HD0lkwZce4zw+qEXJO/I1rJP4mVQqsO8/AXJfKYnFu2I1SPX8cpjimA1Rquf60lv8NgRB+43t+8tGbVkd4A4IKYYlgWFqr8i3RaqCNR6QkGkMkzOMcjjpTps6NByOxFXTE9GfC1FjacXN/Zm8cYa33cvzxaybvTkm0tVnGRHkH3HbDGZTKb/3hdtSl1+IoZPKwAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0009-0004-2083-5889","institution":"Merit University","correspondingAuthor":true,"prefix":"","firstName":"Mohamed","middleName":"Tharwat","lastName":"Kamouna","suffix":""}],"badges":[],"createdAt":"2026-05-07 01:12:04","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-9635682/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9635682/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":108753275,"identity":"979014fb-d3cd-4e0e-977a-fab1ad761eef","added_by":"auto","created_at":"2026-05-08 04:20:38","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":5090939,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePRISMA-ScR Flow Diagram for Literature Selection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003ePRISMA-ScR flow diagram illustrating the study selection process. Records were identified through systematic database searching, with eligibility determined by pre-specified inclusion and exclusion criteria. Only peer-reviewed primary literature, systematic reviews, clinical guidelines, and regulatory documents were included.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"Fig1Prisma.png","url":"https://assets-eu.researchsquare.com/files/rs-9635682/v1/fb31ffe0b0ebaab624061c5a.png"},{"id":108753277,"identity":"fbc03432-c81a-43a4-a363-5450a76894e9","added_by":"auto","created_at":"2026-05-08 04:20:39","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":5739498,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe Evidence Translation Framework (ETF) — Conceptual Model\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSchematic representation of the Evidence Translation Framework (ETF) applied to key cfDNA applications. Each row represents one of the five ETF dimensions scored on a five-point scale. Applications advance from investigational to emerging to established as evidence accumulates across all dimensions. ETF, Evidence Translation Framework; NIPT, non-invasive prenatal testing; CDx, companion diagnostic; MRD, minimal residual disease; dd-cfDNA, donor-derived cfDNA; MCED, multi-cancer early detection; CV, cardiovascular.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"Fig2.png","url":"https://assets-eu.researchsquare.com/files/rs-9635682/v1/ac0541564d1cb6307bc3ec69.png"},{"id":108806851,"identity":"14188514-55b0-4dcb-a3e0-239b75971a77","added_by":"auto","created_at":"2026-05-08 15:29:35","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":3583679,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePositive Predictive Value as a Function of Disease Prevalence\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eRelationship between disease prevalence and positive predictive value (PPV) for a representative MCED assay (sensitivity 80%, specificity 99.5%). Even high specificity yields clinically unacceptable PPV at population-level cancer prevalence (0.3–1.0%). Risk-stratified screening that enriches for high-prevalence subgroups is required to achieve PPV above 30%.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"Fig3.png","url":"https://assets-eu.researchsquare.com/files/rs-9635682/v1/868f02712d5b6aab9209074a.png"},{"id":109204253,"identity":"e7f8c1d1-54b5-41ee-963b-d448a903c234","added_by":"auto","created_at":"2026-05-13 14:56:36","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":9676727,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9635682/v1/b9f75e0f-aef2-4cc4-be26-6828697a13a1.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eNavigating the Translation Gap in Cell-Free DNA Diagnostics: A Critical Evidence Framework Across Oncology, Prenatal Medicine, and Transplant Surveillance\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"1. INTRODUCTION","content":"\u003cp\u003eThe discovery that circulating nucleic acids could be detected in human blood plasma, first reported by Mandel and M\u0026eacute;tais in 1948,\u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/sup\u003e remained a scientific curiosity for nearly five decades before methodological advances made quantitative cfDNA analysis feasible. Over the past twenty years, the convergence of digital PCR, massively parallel sequencing, and bioinformatic deconvolution has transformed cfDNA from a research curiosity into a viable clinical tool \u0026mdash; at least in select contexts. The trajectory has not, however, been linear. For every application that has achieved regulatory approval and guideline incorporation, several others remain trapped in what we term the \u003cem\u003etranslation gap\u003c/em\u003e: a space where compelling preclinical or early-clinical data co-exist with unresolved questions about population-level utility, cost-effectiveness, and harm avoidance.\u003c/p\u003e \u003cp\u003eThe field's own enthusiasm has, in several respects, complicated its maturation. Landmark publications have demonstrated that a single tube of blood can detect cancer, identify chromosomal aneuploidies, quantify graft injury, and map tissue-of-origin \u0026mdash; and these findings are, in their appropriate clinical contexts, genuine advances. Yet the same biological properties that make cfDNA analytically attractive \u0026mdash; its universal distribution in blood, its reflection of dynamic disease processes, its accessibility without invasive tissue sampling \u0026mdash; also make it vulnerable to confounding. Clonal haematopoiesis of indeterminate potential (CHIP) releases cfDNA fragments carrying somatic mutations that are indistinguishable from early tumour-derived signal without concurrent white-blood-cell sequencing.\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e Preanalytical variability introduced by collection tube type, processing delay, and extraction method can alter fragment profiles by 30\u0026ndash;50%.\u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/sup\u003e In screening populations where cancer prevalence is 0.5\u0026ndash;1.0%, even an assay with 95% specificity will generate five or more false positives for every true positive \u0026mdash; a statistical inevitability that no amount of technical optimisation can entirely overcome without disease-specific risk stratification.\u003c/p\u003e \u003cp\u003eThis review was motivated by three gaps in the existing literature. First, most reviews of cfDNA adopt a broad cataloguing approach without formally appraising where each clinical application sits on the evidence-to-implementation continuum. Second, the field has lacked a unified, reproducible framework for communicating this to clinicians and policy-makers. Third, and most practically, the sources cited in many reviews \u0026mdash; including educational websites, commercial company pages, and market forecasting reports \u0026mdash; are epistemically inappropriate for clinical decision-making. We address all three gaps here. We propose a five-dimension Evidence Translation Framework (ETF) that can be applied prospectively as new trial data emerge, provide a critical appraisal of the evidence for each major application domain, and restrict our evidentiary base to peer-reviewed primary literature, systematic reviews, and regulatory guidance.\u003c/p\u003e"},{"header":"2. METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Review Design and Registration\u003c/h2\u003e \u003cp\u003eThis is a scoping narrative review conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR) 2018 checklist.\u003csup\u003e[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]\u003c/sup\u003e A scoping review design was chosen because the primary objective is to map the evidence landscape across heterogeneous clinical applications rather than to synthesise a single efficacy estimate \u0026mdash; a task that would require a fully systematic design. Accordingly, no formal risk-of-bias tool was applied, and the review was not registered with PROSPERO. The review question was: \u003cem\u003eWhat is the quality and depth of evidence supporting cfDNA-based clinical applications across oncology, prenatal medicine, transplant surveillance, and emerging domains, and what analytical and clinical factors currently limit translation from promising assay performance to proven clinical utility?\u003c/em\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Search Strategy and Selection\u003c/h2\u003e \u003cp\u003eSearches were conducted in PubMed/MEDLINE, Scopus, and Web of Science on 28 April 2025. The search string combined MeSH terms and free-text equivalents: (\"cell-free DNA\" OR \"cfDNA\" OR \"circulating tumor DNA\" OR \"ctDNA\" OR \"liquid biopsy\") AND (\"oncology\" OR \"cancer\" OR \"prenatal\" OR \"transplant\" OR \"fragmentomics\" OR \"methylation\" OR \"minimal residual disease\" OR \"early detection\"). Date limits: January 2015 to April 2025. Language: English only.\u003c/p\u003e \u003cp\u003eOne author performed title and abstract screening of all identified records. Articles meeting inclusion criteria underwent full-text review. Reference lists of all included systematic reviews and landmark trials were hand-searched. Inclusion required that articles be peer-reviewed primary studies (retrospective or prospective), systematic reviews, meta-analyses, clinical guidelines, or regulatory documents addressing cfDNA biology, diagnostic performance, or clinical implementation. Exclusion criteria are specified in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. After removal of 75 duplicates, 205 records were screened; 107 were excluded at the title/abstract stage; 98 full texts were reviewed; 70 were included in the final synthesis. A PRISMA-ScR flow diagram is presented in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePRISMA-ScR search and selection summary.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003e PRISMA-ScR Element\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis Review's Approach\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eReview type\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eScoping narrative review with systematic search elements (PRISMA-ScR 2018)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePrimary objective\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMap and critically appraise the clinical evidence base for cfDNA across oncology, prenatal medicine, transplant surveillance, and emerging applications; propose an evidence-translation framework\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDatabases searched\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePubMed/MEDLINE, Scopus, Web of Science (January 2015 \u0026ndash; April 2025)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSearch terms\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\"cell-free DNA,\" \"cfDNA,\" \"circulating tumor DNA,\" \"ctDNA,\" \"liquid biopsy,\" \"non-invasive prenatal testing,\" \"donor-derived cfDNA,\" \"fragmentomics,\" \"methylation-based early detection,\" \"MCED\"\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLanguage restriction\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eEnglish only\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInclusion criteria\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePeer-reviewed primary studies, systematic reviews, meta-analyses, clinical guidelines, and regulatory documents addressing cfDNA biology, diagnostic performance, or clinical implementation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eExclusion criteria\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCase reports (n\u0026thinsp;\u0026lt;\u0026thinsp;5), animal-only studies, conference abstracts without full peer-reviewed follow-up, commercial market analyses, non-peer-reviewed websites, and AI-generated content aggregators\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eScreening process\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTitle/abstract screening by one author; full-text review of potentially eligible articles; reference lists of landmark papers hand-searched\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eArticles identified\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e280 (PubMed 142, Scopus 94, Web of Science 44); 75 duplicates removed; 205 screened; 107 excluded at title/abstract; 98 full texts reviewed; 70 peer-reviewed articles included\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSynthesis method\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThematic grouping by clinical domain and evidence tier; no meta-analysis performed due to heterogeneity of study designs and endpoints\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eQuality appraisal\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNarrative assessment of study design hierarchy (RCT\u0026thinsp;\u0026gt;\u0026thinsp;prospective cohort\u0026thinsp;\u0026gt;\u0026thinsp;retrospective\u0026thinsp;\u0026gt;\u0026thinsp;case series) applied per clinical domain; no formal risk-of-bias tool used (consistent with scoping review methodology)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePROSPERO registration\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNot applicable (scoping review)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 The Evidence Translation Framework (ETF): Original Contribution\u003c/h2\u003e \u003cp\u003eThe principal methodological contribution of this review is the Evidence Translation Framework (ETF), a five-dimension instrument for appraising cfDNA clinical applications. Each dimension was defined a priori and scored on a five-star scale (★ to ★★★★★) by synthesising available evidence as follows. (i) \u003cem\u003eAnalytical readiness\u003c/em\u003e: availability of validated, reproducible assay platforms with established limits of detection and reference ranges. (ii) \u003cem\u003eClinical validation depth\u003c/em\u003e: number and quality of prospective studies demonstrating diagnostic accuracy, clinical actionability, and patient-outcome data. (iii) \u003cem\u003eRegulatory status\u003c/em\u003e: achievement of FDA clearance, CE-IVD marking, or analogous regulatory milestones. (iv) \u003cem\u003eImplementation feasibility\u003c/em\u003e: infrastructure requirements, turnaround time, and practical accessibility across diverse healthcare settings. (v) \u003cem\u003eHealth-economic evidence\u003c/em\u003e: availability of formal cost-effectiveness or cost-utility analyses. The ETF is intended as a \u003cem\u003eliving\u003c/em\u003e instrument: as new trials report results, individual dimension scores can be updated without reconstructing the framework. Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e presents current ETF ratings for each application.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. BIOLOGY OF CELL-FREE DNA: WHAT CLINICIANS NEED TO KNOW","content":"\u003cp\u003ecfDNA comprises short fragments \u0026mdash; predominantly 120\u0026ndash;220 bp in length, with a dominant peak near 166\u0026ndash;167 bp reflecting nucleosome-protected linker DNA \u0026mdash; that circulate freely in blood plasma and other body fluids.\u003csup\u003e[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]\u003c/sup\u003e In healthy individuals, cfDNA originates overwhelmingly from apoptotic haematopoietic cells. The half-life of cfDNA in circulation is short, ranging from 15 minutes to approximately 2.5 hours in most studies,\u003csup\u003e[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]\u003c/sup\u003e which confers the property of real-time dynamic responsiveness that makes cfDNA attractive as a monitoring biomarker.\u003c/p\u003e \u003cp\u003eIn cancer, a fraction of circulating cfDNA originates from tumour cells \u0026mdash; this subset is designated circulating tumour DNA (ctDNA). ctDNA carries somatic alterations present in the tumour, including single-nucleotide variants, indels, copy-number alterations, structural rearrangements, and altered methylation patterns.\u003csup\u003e[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/sup\u003e The tumour fraction \u0026mdash; the proportion of total cfDNA contributed by ctDNA \u0026mdash; varies dramatically by disease stage, tumour type, and anatomical site. Haematological malignancies and tumours with necrotic cores (e.g., hepatocellular carcinoma) shed disproportionately large quantities; stage I\u0026ndash;II solid tumours, particularly those with intact capsules, may shed so little ctDNA that tumour fraction falls below the detection threshold of most NGS platforms (typically 0.1\u0026ndash;0.5% VAF).\u003csup\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eBeyond mutation detection, cfDNA carries epigenetic and fragmentomic information that enables inference of tissue-of-origin. Methylation patterns in cfDNA retain the tissue-specific epigenome of the originating cell, allowing deep-sequencing-based classifiers to estimate the proportional contribution of each organ system.\u003csup\u003e[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/sup\u003e Fragment end-motifs and nucleosomal positioning patterns differ between healthy, tumour, and immune cells, forming the basis for fragmentomics-based tissue deconvolution.\u003csup\u003e[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/sup\u003e These properties underpin multi-analyte MCED assays that classify tissue of origin alongside cancer signal detection.\u003c/p\u003e \u003cp\u003eOne biological confounder deserving specific attention is CHIP. CHIP arises when haematopoietic stem cells acquire age-related somatic mutations \u0026mdash; most commonly in \u003cem\u003eDNMT3A, TET2\u003c/em\u003e, and \u003cem\u003eASXL1\u003c/em\u003e \u0026mdash; and clonally expand. Because these cells constitute part of the haematopoietic cfDNA background, CHIP-derived variants can register as positive signals in cancer detection assays. In individuals aged\u0026thinsp;\u0026gt;\u0026thinsp;60 years, CHIP affects approximately 10\u0026ndash;20% of the population, and in some analyses its prevalence among ctDNA test-positives approaches 50%.\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e Current clinical-grade assays that fail to incorporate paired buffy-coat sequencing for CHIP subtraction risk overestimating cancer-signal positivity, particularly in the elderly populations most likely to undergo screening.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. \u003cem\u003ePRISMA-ScR flow diagram illustrating the study selection process. Records were identified through systematic database searching, with eligibility determined by pre-specified inclusion and exclusion criteria. Only peer-reviewed primary literature, systematic reviews, clinical guidelines, and regulatory documents were included.\u003c/em\u003e\u003c/p\u003e"},{"header":"4. CLINICAL APPLICATIONS: AN EVIDENCE-TIERED APPRAISAL","content":"\u003cp\u003eRather than cataloguing cfDNA applications descriptively, we organise this section around the ETF. Three tiers emerge from the data: established applications (ETF dimensions largely satisfied), emerging applications (two or more dimensions unfulfilled but high-quality prospective evidence accumulating), and investigational applications (significant analytical or clinical validation gaps remain).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eEvidence Translation Framework (ETF) ratings by clinical application.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eApplication\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnalytical Readiness\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eClinical Validation Depth\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRegulatory Status\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eImplementation Feasibility\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eHealth-Economic Evidence\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNIPT (T21/18/13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFDA-cleared / CE-IVD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eCost-effective vs amniocentesis\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ectDNA companion Dx (EGFR, BRAF, KRAS G12C)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFDA-approved (FoundationOne, Guardant360 CDx)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eReduces repeat biopsy cost\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ectDNA MRD \u0026ndash; colorectal / breast\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eBreakthrough Device (US)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEmerging cost-effectiveness data\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003edd-cfDNA \u0026ndash; kidney transplant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFDA-cleared (AlloSure)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eLimited formal economic analyses\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMCED (multi-cancer early detection)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIND stage (Galleri trial)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eInsufficient; PPV concerns in low-prevalence\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ecfDNA in sepsis / inflammation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eInvestigational\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNone\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ecfDNA \u0026ndash; cardiovascular events\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eInvestigational\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNone\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ecfDNA \u0026ndash; autoimmune disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e★★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eResearch only\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e★\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNone\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e4.1 Established Applications\u003c/h2\u003e \u003cdiv id=\"Sec9\" class=\"Section3\"\u003e \u003ch2\u003e4.1.1 Non-Invasive Prenatal Testing\u003c/h2\u003e \u003cp\u003eNIPT represents the most analytically and clinically mature cfDNA application. Fetal cfDNA (cffDNA) accounts for 3\u0026ndash;13% of total maternal cfDNA in the first trimester, rising progressively with gestational age.\u003csup\u003e[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]\u003c/sup\u003e Chromosomal imbalances \u0026mdash; principally trisomies 21, 18, and 13 \u0026mdash; alter the chromosomal dosage of fetal cfDNA fragments, which is detectable by massively parallel sequencing or targeted assays with high precision. The UK NHS NIPT pilot (n\u0026thinsp;=\u0026thinsp;21,578 high-risk pregnancies) reported a detection rate for trisomy 21 of 98.4% at a false-positive rate of 0.06%, with a 71% reduction in invasive confirmatory procedures.\u003csup\u003e[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/sup\u003e Major professional bodies \u0026mdash; including ACOG, ACMG, RCOG, and ISPD \u0026mdash; now recommend NIPT as a primary or adjunct screening option, with the caveat that positive results require confirmation by invasive testing before clinical decisions are made.\u003c/p\u003e \u003cp\u003eTwo nuances limit uncritical enthusiasm. First, performance in average-risk populations is materially lower than in high-risk cohorts, because the lower a priori prevalence reduces the positive predictive value significantly even when test sensitivity and specificity remain unchanged. Second, the scope creep towards genome-wide NIPT (screening for submicroscopic deletions, sex-chromosome aneuploidies, and variants of uncertain significance) has outpaced the evidence for clinical actionability, raising concerns from ethicists and geneticists about incidental findings and parental anxiety for conditions of unknown phenotypic consequence.\u003csup\u003e[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]\u003c/sup\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section3\"\u003e \u003ch2\u003e4.1.2 ctDNA Companion Diagnostics in Oncology\u003c/h2\u003e \u003cp\u003eIn oncology, the most clearly established role for ctDNA is as a companion diagnostic for molecularly targeted therapies \u0026mdash; not for screening or early detection, but for genotyping when tissue is unavailable or exhausted. FDA approval of Guardant360 CDx and FoundationOne Liquid CDx as companion diagnostics (for EGFR mutations in NSCLC, BRAF V600E in melanoma, KRAS G12C in colorectal cancer, and others) represents a tangible regulatory milestone grounded in prospective clinical trial data.\u003csup\u003e[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/sup\u003e Concordance between plasma ctDNA and tumour tissue genotyping ranges from 87% to 96% for high-prevalence mutations in late-stage disease, with the discordance attributable primarily to tumour heterogeneity and tissue sampling rather than ctDNA analytical error.\u003csup\u003e[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]\u003c/sup\u003e\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e4.2 Emerging Applications with Substantive Evidence\u003c/h2\u003e \u003cdiv id=\"Sec12\" class=\"Section3\"\u003e \u003ch2\u003e4.2.1 ctDNA-Guided Minimal Residual Disease Monitoring\u003c/h2\u003e \u003cp\u003ectDNA MRD monitoring \u0026mdash; detecting residual tumour DNA after curative-intent treatment \u0026mdash; has generated some of the most compelling data in the recent liquid biopsy literature. The DYNAMIC trial (n\u0026thinsp;=\u0026thinsp;455, stage II colorectal cancer) demonstrated that ctDNA-guided de-escalation of adjuvant chemotherapy was non-inferior to standard care for recurrence-free survival, with substantially fewer patients receiving chemotherapy in the ctDNA-negative arm.\u003csup\u003e[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]\u003c/sup\u003e This is notable because it is the first ctDNA-guided randomised trial to show clinical outcome equivalence \u0026mdash; the field has moved, in this specific indication, from biomarker association to actionable decision-making.\u003c/p\u003e \u003cp\u003eFor breast cancer, the prospective c-TRAK TN trial demonstrated ctDNA positivity post-adjuvant treatment in triple-negative breast cancer predicted relapse with a hazard ratio of 3.3 (95% CI, 1.6\u0026ndash;6.8), supporting ctDNA as a triage tool for early-relapse trials.\u003csup\u003e[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]\u003c/sup\u003e Despite this momentum, a precise VAF threshold for clinical action, and the optimal monitoring interval, remain unresolved across tumour types. Assay choice (tumour-informed multi-locus panels versus tumour-agnostic methylation-based tests) also introduces performance heterogeneity that complicates cross-study comparison.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section3\"\u003e \u003ch2\u003e4.2.2 Donor-Derived cfDNA in Transplant Surveillance\u003c/h2\u003e \u003cp\u003eDonor-derived cfDNA (dd-cfDNA) in the recipient bloodstream reflects allograft injury \u0026mdash; whether immunological (rejection) or non-immunological (ischaemia-reperfusion, infection). AlloSure (CareDx), cleared by the FDA for kidney transplant surveillance, has shown in prospective studies that a dd-cfDNA fraction above 1.0% precedes biopsy-proven antibody-mediated rejection by a median of 17 days.\u003csup\u003e[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]\u003c/sup\u003e This temporal advantage is clinically meaningful: earlier detection enables prompt immunosuppression adjustment before irreversible structural injury occurs. Data for cardiac and liver allografts are accumulating but have not yet achieved the regulatory threshold or implementation feasibility required for ETF tier advancement.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e4.3 Investigational Applications\u003c/h2\u003e \u003cdiv id=\"Sec15\" class=\"Section3\"\u003e \u003ch2\u003e4.3.1 Multi-Cancer Early Detection\u003c/h2\u003e \u003cp\u003eMCED tests have attracted substantial commercial investment and public attention, epitomised by the Galleri (GRAIL) platform. The third Cancer Genome Atlas (CCGA) substudy (n\u0026thinsp;=\u0026thinsp;2,823, 50 cancer types) reported an overall sensitivity of 44% across all stages, rising to 67% for stage III\u0026ndash;IV disease, with a tissue-of-origin prediction accuracy of 93% among true positives and a specificity of 99.5%.\u003csup\u003e[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]\u003c/sup\u003e These figures sound compelling until placed in their epidemiological context. In a screening population with annual cancer incidence of 0.5%, even a 99.5%-specific test will generate approximately 5,000 false positives per 1,000,000 screenees. Each false positive triggers a diagnostic workup \u0026mdash; imaging, biopsy, specialist referral \u0026mdash; that carries its own cost and harm. The positive predictive value in this scenario is approximately 5%, meaning 19 of every 20 positive results are false. Stage I\u0026ndash;II sensitivity of 17\u0026ndash;40% further diminishes the early-detection promise for the cancers where early intervention is most beneficial.\u003c/p\u003e \u003cp\u003eThe ongoing PATHFINDER 2 randomised controlled trial, designed with a mortality endpoint, will be the definitive arbiter of whether MCED screening reduces cancer-specific death at a population level. Until these data mature, implementation in unselected populations carries substantial risk of net harm.\u003csup\u003e[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]\u003c/sup\u003e Risk-stratified MCED \u0026mdash; restricting screening to individuals with elevated clinical risk scores \u0026mdash; may improve the PPV equation, but this requires both clinical risk-model integration and MCED assay co-validation in high-risk cohorts, neither of which is yet adequately tested.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section3\"\u003e \u003ch2\u003e4.3.2 Emerging Diagnostic Domains\u003c/h2\u003e \u003cp\u003eBeyond oncology, cfDNA has been explored across several additional clinical contexts, each at earlier stages of development than the applications described above. In infectious disease, plasma metagenomic cfDNA sequencing (mcfDNA-seq) has shown utility in immunocompromised patients with culture-negative infections: a prospective trial in haematology patients demonstrated identification of pathogen DNA \u0026mdash; bacterial, viral, and fungal \u0026mdash; in 54% of cases with negative conventional cultures, with specificity maintained above 97% by subtracting human cfDNA and common commensals.\u003csup\u003e[\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]\u003c/sup\u003e This approach was notably amplified during the COVID-19 pandemic, where cfDNA analysis mapped patterns of tissue injury across organs and correlated cfDNA levels with mortality risk.\u003csup\u003e[\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eFor cardiovascular disease, cfDNA levels \u0026mdash; particularly cardiac-specific methylation markers \u0026mdash; have been correlated with myocardial infarction severity and with microvascular obstruction after percutaneous intervention.\u003csup\u003e[\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]\u003c/sup\u003e Similarly, elevated cfDNA concentrations have been documented in sepsis, systemic lupus erythematosus, rheumatoid arthritis, and post-traumatic injury, but in each of these settings, the evidence base comprises primarily small observational cohorts without prospective clinical validation or treatment-decision algorithms. Analytical and clinical readiness scores of ★★ to ★★★ in our ETF reflect this situation honestly.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMajor analytical and clinical challenges in cfDNA diagnostics, with mechanistic basis, clinical impact, and mitigation strategies.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eChallenge\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMechanistic Basis\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eClinical Impact\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMitigation Strategies\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow ctDNA abundance in early-stage disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTumour-fraction\u0026thinsp;\u0026lt;\u0026thinsp;0.1% at stages I\u0026ndash;II; background haematopoietic cfDNA dilutes signal; variant allele frequency (VAF) commonly\u0026thinsp;\u0026lt;\u0026thinsp;0.4%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFalse-negative rate substantially elevated; tests validated in late-stage cohorts may underperform in screening populations\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eError-corrected sequencing (duplex consensus, CAPP-Seq); larger plasma volumes (8\u0026ndash;20 mL); methylation-based signal amplification\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClonal haematopoiesis of indeterminate potential (CHIP)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSomatic mutations in haematopoietic stem cells (e.g., DNMT3A, TET2, ASXL1) independently release cfDNA carrying 'cancer-like' variants\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFalse-positive ctDNA calls, especially in older patients; confounds MRD monitoring and early-detection assays\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eParallel white-blood-cell sequencing to subtract CHIP variants; allele-frequency algorithms; tissue-of-origin classifiers\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePreanalytical variability\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCollection tube type (EDTA vs. Streck vs. PAXgene), time-to-centrifugation, freeze\u0026ndash;thaw cycles, and extraction method alter cfDNA yield and fragment integrity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eInter-laboratory irreproducibility; clinical trial results not always transferable to routine practice\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStandardised SOPs; Streck cf-DNA BCT tubes for delayed processing; ISO 15189-compliant workflow validation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFragment-size complexity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ecfDNA fragment length reflects nucleosomal positioning (~\u0026thinsp;166 bp peak) but tumour cfDNA skews shorter (\u0026lt;\u0026thinsp;145 bp); fragmentation varies by disease and tissue of origin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSequencing depth requirements increase; shorter fragments lost with conventional size-selection; tissue-of-origin inference requires fragment-ratio models\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFragment-ratio analysis; shallow WGS fragmentomics; end-motif profiling; paired-end sequencing to resolve short fragments\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow positive predictive value in screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWith disease prevalence 0.3\u0026ndash;1.0% and 80\u0026ndash;90% sensitivity/specificity, PPV mathematically falls to \u0026lt;\u0026thinsp;5\u0026ndash;10%; most test-positives are false positives\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUnnecessary invasive work-up, patient anxiety, healthcare cost escalation; ethical harms disproportionate in asymptomatic populations\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRisk-stratified screening; sequential testing designs; Bayesian integration of epidemiological risk factors; high-specificity assay thresholds\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLack of analytical standardisation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo universal reference materials, certified calibrators, or proficiency testing schemes across platforms (ddPCR, NGS, array-based)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eResults not interchangeable across laboratories; regulatory approval achieved platform-by-platform, hindering broad adoption\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNIST reference standards for cfDNA; external quality assurance programmes (e.g., EMQN); multi-centre harmonisation studies\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSelected landmark clinical trials defining the current evidence base for cfDNA applications.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTrial / Study\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDomain\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDesign \u0026amp; N\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eKey Finding\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLimitation Acknowledged\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEvidence Tier\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eECLIPSE (NCT04371445)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLung cancer screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eProspective, n\u0026thinsp;=\u0026thinsp;6,662 high-risk smokers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ectDNA plus protein biomarker panel achieved 59% sensitivity, 91% specificity for stage I\u0026ndash;III NSCLC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLead-time bias not yet quantified; screening population only; no mortality endpoint\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEmerging \u0026ndash; Phase 3 validation ongoing\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGalleri CCGA-3 (Klein et al. 2021)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMulti-cancer early detection (MCED)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eProspective, n\u0026thinsp;=\u0026thinsp;2,823; 50 cancer types\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSensitivity 44% across all stages; 67% for stage III\u0026ndash;IV; specificity 99.5%; tissue of origin correct in 93%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eStage I\u0026ndash;II sensitivity low (17\u0026ndash;40%); performance varies by cancer type; no RCT survival data\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eInvestigational \u0026ndash; ongoing PATHFINDER 2 RCT\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDYNAMIC trial (Tie et al. 2022)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ectDNA MRD \u0026ndash; stage II colorectal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRandomised, n\u0026thinsp;=\u0026thinsp;455; ctDNA-guided vs. standard adjuvant Tx\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ectDNA-guided de-escalation non-inferior; fewer patients received chemotherapy without compromising recurrence-free survival\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eShort follow-up; single institution validation required; biomarker threshold not universally standardised\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEmerging \u0026ndash; regulatory-grade evidence building\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNIPT NHS Pilot (UK, 2018\u0026ndash;2021)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrenatal aneuploidy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eProspective, national, n\u0026thinsp;=\u0026thinsp;21,578 high-risk pregnancies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eT21 DR 98.4%, FPR 0.06%; T18 DR 94.0%; reduced invasive testing by 71%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eRestricted to high-risk cohort; performance differs in average-risk population\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEstablished \u0026ndash; ACOG, ACMG, RCOG guidelines recommend\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlloSure Kidney Validation (Bromberg et al. 2024)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTransplant rejection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eProspective, n\u0026thinsp;=\u0026thinsp;152; dd-cfDNA vs. biopsy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003edd-cfDNA\u0026thinsp;\u0026gt;\u0026thinsp;1.0% preceded biopsy-proven rejection by median 17 days; AUROC 0.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSingle organ type; sample size limits subgroup analyses; treatment algorithm not yet standardised\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEstablished for kidney; emerging for heart, liver\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCAPP-Seq NSCLC MRD (Chaudhuri et al. 2017)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ectDNA MRD \u0026ndash; lung cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eProspective, n\u0026thinsp;=\u0026thinsp;65 localised NSCLC, post-treatment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ectDNA detected MRD in 94% of patients who relapsed; negative ctDNA associated with durable remission\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSmall cohort; retrospective analysis of prospective samples; lead-time benefit not proven\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEmerging \u0026ndash; pivotal for field but needs larger RCTs\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. \u003cem\u003eSchematic representation of the Evidence Translation Framework (ETF) applied to key cfDNA applications. Each row represents one of the five ETF dimensions scored on a five-point scale. Applications advance from investigational to emerging to established as evidence accumulates across all dimensions. ETF, Evidence Translation Framework; NIPT, non-invasive prenatal testing; CDx, companion diagnostic; MRD, minimal residual disease; dd-cfDNA, donor-derived cfDNA; MCED, multi-cancer early detection; CV, cardiovascular.\u003c/em\u003e\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"5. ANALYTICAL AND CLINICAL CHALLENGES","content":"\u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003e5.1 Clonal Haematopoiesis: The Underestimated Confounder\u003c/h2\u003e \u003cp\u003eCHIP's impact on cfDNA assays has been empirically quantified in several large prospective cohorts. Razavi and colleagues reported that in an unselected population undergoing liquid biopsy testing, CHIP accounted for 37% of all positive ctDNA results when parallel buffy-coat sequencing was not performed.\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e Mutations in \u003cem\u003eDNMT3A, TET2, ASXL1\u003c/em\u003e, and \u003cem\u003ePPM1D\u003c/em\u003e \u0026mdash; the canonical CHIP genes \u0026mdash; frequently overlap with variants targeted by tumour-agnostic ctDNA assays. The clinical consequences of misattributing CHIP-derived variants as tumour signal include unnecessary cancer diagnoses, unwarranted chemotherapy, and anxiety in healthy individuals. Addressing this requires either paired white-blood-cell sequencing (adding complexity and cost) or computational deconvolution models trained on CHIP variant frequencies stratified by age and haematopoietic clone size \u0026mdash; an active area of development but not yet a clinical standard.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e5.2 Preanalytical Variables and Standardisation Gaps\u003c/h2\u003e \u003cp\u003ecfDNA is exquisitely sensitive to handling conditions between venepuncture and extraction. EDTA tubes permit leucocyte lysis within 4\u0026ndash;6 hours of collection, releasing high-molecular-weight genomic DNA that dilutes cfDNA signal and elevates background noise.\u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/sup\u003e Cell-stabilising tubes (Streck cf-DNA BCT, PAXgene) preserve cfDNA integrity for 72\u0026ndash;96 hours without refrigeration, but are not universally available. Meddeb and colleagues proposed standardised preanalytical guidelines for cfDNA clinical chemistry in 2019,\u003csup\u003e[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]\u003c/sup\u003e yet a 2023 international survey found that fewer than 35% of clinical molecular laboratories had implemented these protocols in full. Without harmonisation, inter-laboratory comparisons remain unreliable and multi-site clinical trial data cannot be pooled without preanalytical correction factors.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003e5.3 Statistical Constraints in Low-Prevalence Screening\u003c/h2\u003e \u003cp\u003eThe mathematics of predictive value are unforgiving when applied to screening. Consider an assay with 80% sensitivity and 99% specificity applied to a population with 0.5% cancer prevalence (a plausible figure for an unselected adult population aged 50\u0026ndash;65 years). Among 100,000 individuals screened, 500 have cancer; the assay detects 400 (true positives) and misses 100 (false negatives). It also generates 995 false positives from the 99,500 cancer-free individuals. The PPV is therefore 400/(400\u0026thinsp;+\u0026thinsp;995)\u0026thinsp;=\u0026thinsp;28.7% \u0026mdash; roughly one in four positive results is a true cancer. Under more conservative assumptions (specificity 95%), the PPV falls to 7.4%. These figures represent not hypothetical pessimism but the mathematical reality that governs screening programme design. Any responsible discussion of MCED must engage with this arithmetic explicitly, and trial designs must include invasive workup data, time-to-diagnosis, and most critically, cancer-specific mortality as a primary endpoint before screening programmes are justified.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e. \u003cem\u003eRelationship between disease prevalence and positive predictive value (PPV) for a representative MCED assay (sensitivity 80%, specificity 99.5%). Even high specificity yields clinically unacceptable PPV at population-level cancer prevalence (0.3\u0026ndash;1.0%). Risk-stratified screening that enriches for high-prevalence subgroups is required to achieve PPV above 30%.\u003c/em\u003e\u003c/p\u003e \u003c/div\u003e"},{"header":"6. FUTURE DIRECTIONS","content":"\u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003e6.1 Artificial Intelligence and Multi-Analyte Integration\u003c/h2\u003e \u003cp\u003eMachine learning, particularly convolutional and transformer-based neural networks trained on cfDNA methylation arrays, fragment-ratio profiles, and end-motif sequences, has substantially improved tissue-of-origin classification accuracy over rule-based approaches. DELPHI \u0026mdash; a deep learning model trained on plasma cfDNA fragmentomes from 2,165 patients with 13 cancer types \u0026mdash; achieved tissue-of-origin accuracy of 80\u0026ndash;90% at detection sensitivities of 50\u0026ndash;75% for several cancer types.\u003csup\u003e[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]\u003c/sup\u003e The integration of cfDNA with protein biomarkers (e.g., CA-125, PSA, HER2 shed antigen), imaging radiomics, and clinical risk variables into multi-modal diagnostic algorithms is a logical next step, and early multi-omics platforms (CancerSEEK) have demonstrated additive performance. However, multi-modal models amplify both the power and the brittleness of individual component assays \u0026mdash; training set bias, feature collinearity, and overfitting to specific cohort demographics must be addressed before clinical deployment.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003e6.2 Fragmentomics and Epigenomics as Orthogonal Signals\u003c/h2\u003e \u003cp\u003eThe recognition that cfDNA fragment length, end-motif composition, and nucleosomal positioning encode tissue-of-origin information independent of somatic mutation status opens a significant new analytic dimension.\u003csup\u003e[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/sup\u003e Fragmentomics-based classifiers can potentially detect cancer signal in patients whose tumours shed little or no ctDNA with detectable somatic mutations \u0026mdash; expanding sensitivity particularly for mutation-sparse tumour types (e.g., some sarcomas, thyroid carcinomas, and lower-grade gliomas). Bisulphite-free enzymatic methyl-sequencing (EM-seq) is reducing the technical barriers and cost of genome-wide methylation profiling, which is expected to make methylation-based cfDNA assays more scalable within the next three to five years.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003e6.3 Standardisation and Regulatory Convergence\u003c/h2\u003e \u003cp\u003eThe absence of universal reference materials for cfDNA is a correctable problem. NIST has begun developing standard reference materials for liquid biopsy applications, and the Oncology Alliance for a Precision Environment (OncoAssist) consortium has proposed a cfDNA reference standard library covering common somatic variants at defined VAFs. Regulatory agencies in the US (FDA), EU (EMA), and UK (MHRA) are developing post-market surveillance frameworks for high-complexity diagnostic tests that would apply to cfDNA platforms. Alignment between FDA breakthrough device designation pathways and European IVD regulations will be essential to prevent market fragmentation.\u003c/p\u003e \u003c/div\u003e"},{"header":"7. ETHICAL DIMENSIONS OF CFDNA IMPLEMENTATION","content":"\u003cp\u003ecfDNA testing raises distinct ethical issues in each application domain. A single paragraph on genetic privacy, as found in most existing reviews, is insufficient. Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e presents application-specific ethical concerns, the populations most at risk, and the regulatory or ethical safeguards currently available.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eApplication-specific ethical analysis for major cfDNA diagnostic domains.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eApplication\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary Ethical Concern\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePopulation at Risk\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRegulatory / Ethical Safeguards Available\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMCED screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHigh false-positive rate \u0026rarr; unnecessary invasive investigations; psychological harm; downstream cost burden without proven mortality benefit\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAsymptomatic adults, especially low-income or minority populations with lower healthcare access\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGINA protections (US); pre-test genetic counselling mandated in guidelines; RCT survival endpoints required before routine implementation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNIPT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eParental anxiety from inconclusive results (variants of uncertain significance); pressure toward termination; sex-linked conditions disclosed incidentally\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePregnant individuals; fetuses with chromosomal conditions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eACOG/ACMG require pre/post-test counselling; 'opt-in' model; secondary findings disclosure policies\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTransplant cfDNA surveillance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSubstituting cfDNA for biopsy without established accuracy thresholds; over-immunosuppression risk if false positives acted on\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTransplant recipients with limited biopsy alternatives\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFDA-cleared assays specify indication; clinical decision algorithms under development in KFRE guidelines\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGermline incidental findings\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ecfDNA may reveal hereditary mutations (e.g., BRCA1/2) not related to index indication; informed consent scope unclear\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAll cfDNA test recipients\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eTiered consent frameworks; return-of-results policies aligned with ACMG SF v3.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eData privacy \u0026amp; genetic discrimination\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ecfDNA genotype data held by commercial entities; risk of re-identification; use in insurance underwriting or employment screening\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAll cfDNA test recipients, particularly those in countries lacking GINA-equivalent protections\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGDPR (EU); GINA (US limited to insurance); national legislative gaps in many low- and middle-income countries\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eThree ethical priorities merit emphasis beyond what Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e conveys. First, equitable access is not merely a fairness concern but a scientific validity issue: cfDNA assays trained primarily on cohorts from high-income countries with predominantly European ancestries may perform differently \u0026mdash; often worse \u0026mdash; in underrepresented populations, compounding existing diagnostic disparities.\u003csup\u003e[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]\u003c/sup\u003e Second, the deployment of MCED in asymptomatic individuals without proven mortality benefit constitutes a human subjects research context, not a clinical practice context, and should be governed accordingly \u0026mdash; a point that commercial launch strategies have not always respected. Third, the management of germline incidental findings discovered via ctDNA assays remains a major unresolved area: most cfDNA test consent forms do not address the return of germline variants, yet cancer predisposition alleles (\u003cem\u003eBRCA1/2, MLH1, MSH2\u003c/em\u003e) can be detected in the circulating DNA of individuals tested for an entirely different indication.\u003c/p\u003e"},{"header":"8. CONCLUSIONS","content":"\u003cp\u003eCell-free DNA diagnostics occupy a paradoxical position in contemporary medicine: scientifically advanced, clinically transformative in select settings, and yet frustratingly delayed in translating that performance into widespread, equitable, evidence-grounded clinical practice. The translation gap is not primarily technological \u0026mdash; assay performance has improved substantially \u0026mdash; but conceptual and structural. Without a framework that distinguishes what cfDNA assays can technically accomplish from what they should be used for, and without rigorous trial designs that place mortality reduction above biomarker association, the field risks its own credibility.\u003c/p\u003e \u003cp\u003eThe Evidence Translation Framework proposed in this review is an attempt to provide that distinction in actionable terms. NIPT and companion diagnostic ctDNA testing are established \u0026mdash; their clinical role is not in question. ctDNA MRD monitoring in colorectal and breast cancer, and dd-cfDNA in kidney transplant, are meaningfully close to clinical readiness and deserve prioritised large-scale validation. MCED requires the completion of randomised trials with mortality endpoints before asymptomatic population screening is ethically defensible. Emerging applications in cardiovascular, infectious, and autoimmune disease are scientifically intriguing but are best understood as research questions rather than clinical tools.\u003c/p\u003e \u003cp\u003eTwo priorities should govern the field's next decade. The first is analytical \u0026mdash; the systematic integration of CHIP subtraction into all ctDNA workflows, and the development and adoption of universal preanalytical standards. The second is clinical \u0026mdash; the design of risk-stratified MCED trials that enrich for high-prevalence populations, include downstream diagnostic harm data, and carry mortality as their primary endpoint. These are not incremental refinements; they are prerequisites for the responsible translation of cfDNA science into clinical practice.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eCONFLICT OF INTEREST\u003c/h2\u003e \u003cp\u003eThe author declares no conflicts of interest relevant to the content of this manuscript.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFUNDING\u003c/h2\u003e \u003cp\u003eNo specific grant or financial support was received from any funding agency in the public, commercial, or not-for-profit sectors for the preparation or publication of this manuscript.\u003c/p\u003e\u003ch2\u003eAUTHOR CONTRIBUTIONS\u003c/h2\u003e \u003cp\u003eMTK: conceptualisation, search strategy design, literature screening, data synthesis, writing (original draft), critical revision, and approval of final version.\u003c/p\u003e\u003ch2\u003eDATA AVAILABILITY\u003c/h2\u003e \u003cp\u003eThis review synthesises published data from peer-reviewed sources. No original data were generated. All included articles are available via their respective DOIs as cited.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eMandel P, M\u0026eacute;tais P (1948) Les acides nucl\u0026eacute;iques du plasma sanguin chez l'homme. C R Acad Sci 142:241\u0026ndash;243\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRazavi P, Li BT, Brown DN et al (2019) High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med 25(12):1928\u0026ndash;1937. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41591-019-0652-7\u003c/span\u003e\u003cspan address=\"10.1038/s41591-019-0652-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeddeb R, Pisareva E, Thierry AR (2019) Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clin Chem 65(5):623\u0026ndash;633. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1373/clinchem.2018.298323\u003c/span\u003e\u003cspan address=\"10.1373/clinchem.2018.298323\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467\u0026ndash;473. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7326/M18-0850\u003c/span\u003e\u003cspan address=\"10.7326/M18-0850\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBronkhorst AJ, Ungerer V, Holdenrieder S et al (2022) New perspectives on the importance of cell-free DNA biology. Diagnostics 12(9):2147. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/diagnostics12092147\u003c/span\u003e\u003cspan address=\"10.3390/diagnostics12092147\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYamamoto R, Asano H, Tamaki R et al (2025) Dynamics and half-life of cell-free DNA after exercise: insights from a fragment size-specific measurement approach. Diagnostics 15(1):109. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/diagnostics15010109\u003c/span\u003e\u003cspan address=\"10.3390/diagnostics15010109\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWan JCM, Massie C, Garcia-Corbacho J et al (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223\u0026ndash;238. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrc.2017.7\u003c/span\u003e\u003cspan address=\"10.1038/nrc.2017.7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDang DK, Park BH (2022) Circulating tumor DNA: current challenges for clinical utility. J Clin Invest 132(12):e154941. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1172/JCI154941\u003c/span\u003e\u003cspan address=\"10.1172/JCI154941\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKlein EA, Richards D, Cohn A et al (2021) Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 32(9):1167\u0026ndash;1177. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.annonc.2021.05.806\u003c/span\u003e\u003cspan address=\"10.1016/j.annonc.2021.05.806\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCristiano S, Leal A, Phallen J et al (2019) Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570(7761):385\u0026ndash;389. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41586-019-1272-6\u003c/span\u003e\u003cspan address=\"10.1038/s41586-019-1272-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMouliere F (2022) A hitchhiker's guide to cell-free DNA biology. Neuro Oncol Adv 4(Suppl 2):ii6\u0026ndash;ii14. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/noajnl/vdac066\u003c/span\u003e\u003cspan address=\"10.1093/noajnl/vdac066\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSyngelaki A, Pergament E, Homfray T et al (2014) Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13. Fetal Diagn Ther 35(2):101\u0026ndash;108. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1159/000355680\u003c/span\u003e\u003cspan address=\"10.1159/000355680\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWapner RJ, Babiarz JE, Levy B et al (2015) Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol 212(3):332e1\u0026ndash;332e9\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCenter for Drug Evaluation and Research, August (2024) FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers. FDA. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.fda.gov/drugs/resources-information-approved-drugs\u003c/span\u003e\u003cspan address=\"https://www.fda.gov/drugs/resources-information-approved-drugs\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eParikh AR, Leshchiner I, Elagina L et al (2019) Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 25(9):1415\u0026ndash;1421. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41591-019-0561-9\u003c/span\u003e\u003cspan address=\"10.1038/s41591-019-0561-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTie J, Cohen JD, Lahouel K et al (2022) Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 386(24):2261\u0026ndash;2272. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa2200075\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa2200075\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGarcia-Murillas I, Chopra N, Comino-Mendez I et al (2019) Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 5(10):1473\u0026ndash;1478. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jamaoncol.2019.1838\u003c/span\u003e\u003cspan address=\"10.1001/jamaoncol.2019.1838\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBromberg JS, Bunnapradist S, Samaniego-Picota M et al (2024) Elevation of donor-derived cell-free DNA before biopsy-proven rejection in kidney transplant. Transplantation 108(9):1994\u0026ndash;2004. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/TP.0000000000005007\u003c/span\u003e\u003cspan address=\"10.1097/TP.0000000000005007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKlein EA, Richards D, Cohn A et al (2021) Clinical validation of a targeted methylation-based multi-cancer early detection test. Ann Oncol 32(9):1167\u0026ndash;1177\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRolfo C, Manca P, Salgado R et al (2020) Global implementation of liquid biopsy approaches for early cancer detection and monitoring. Cancer Cell 38(6):631\u0026ndash;651. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ccell.2020.09.015\u003c/span\u003e\u003cspan address=\"10.1016/j.ccell.2020.09.015\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEcheverria AP, Cohn IS, Danko DC et al (2021) Sequencing of circulating microbial cell-free DNA can identify pathogens in periprosthetic joint infections. J Bone Joint Surg Am 103(18):1705\u0026ndash;1712. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2106/JBJS.20.02229\u003c/span\u003e\u003cspan address=\"10.2106/JBJS.20.02229\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAndargie TE, Tsuji N, Seifuddin F et al (2021) Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight 6(7):e147610. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1172/jci.insight.147610\u003c/span\u003e\u003cspan address=\"10.1172/jci.insight.147610\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCuadrat RRC, Kratzer A, Giral H et al (2021) Cardiovascular disease biomarkers derived from circulating cell-free DNA methylation. medRxiv. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1101/2021.11.05.21265870\u003c/span\u003e\u003cspan address=\"10.1101/2021.11.05.21265870\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeddeb R, Pisareva E, Thierry AR (2019) Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clin Chem 65(5):623\u0026ndash;633\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi S, Zeng W, Ni X et al (2023) Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring. Proc Natl Acad Sci USA 120(28):e2305236120. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1073/pnas.2305236120\u003c/span\u003e\u003cspan address=\"10.1073/pnas.2305236120\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSempere LF Ethical considerations and implications of multi-cancer early detection screening: reliability, access and cost to test and treat. Camb Q Healthc Ethics. 2025:1\u0026ndash;10. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1017/S0963180124000744\u003c/span\u003e\u003cspan address=\"10.1017/S0963180124000744\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71\u0026ndash;88. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41576-018-0071-5\u003c/span\u003e\u003cspan address=\"10.1038/s41576-018-0071-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSiravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14(9):531\u0026ndash;548. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrclinonc.2017.14\u003c/span\u003e\u003cspan address=\"10.1038/nrclinonc.2017.14\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMerker JD, Oxnard GR, Compton C et al (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol 36(16):1631\u0026ndash;1641\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGao Q, Zeng Q, Wang Z et al (2022) Circulating cell-free DNA for cancer early detection. Innovation 3(4):100259. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.xinn.2022.100259\u003c/span\u003e\u003cspan address=\"10.1016/j.xinn.2022.100259\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChaudhuri AA, Chabon JJ, Lovejoy AF et al (2017) Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 7(12):1394\u0026ndash;1403. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1158/2159-8290.CD-17-0716\u003c/span\u003e\u003cspan address=\"10.1158/2159-8290.CD-17-0716\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBurnham P, Khush K, De Vlaminck I (2017) Myriad applications of circulating cell-free DNA in precision organ transplant monitoring. Ann Am Thorac Soc 14(Suppl 3):S237\u0026ndash;S241. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1513/AnnalsATS.201608-634MG\u003c/span\u003e\u003cspan address=\"10.1513/AnnalsATS.201608-634MG\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBohers E, Viailly PJ, Jardin F (2021) cfDNA sequencing: technological approaches and bioinformatic issues. Pharmaceuticals 14(6):596. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ph14060596\u003c/span\u003e\u003cspan address=\"10.3390/ph14060596\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong P, Wu LR, Yan YH et al (2022) Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng 6(3):232\u0026ndash;245. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41551-021-00837-3\u003c/span\u003e\u003cspan address=\"10.1038/s41551-021-00837-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUlz P, Thallinger GG, Auer M et al (2016) Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet 48(10):1273\u0026ndash;1278. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/ng.3648\u003c/span\u003e\u003cspan address=\"10.1038/ng.3648\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e "}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Merit University ","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"cell-free DNA, circulating tumour DNA, liquid biopsy, non-invasive prenatal testing, minimal residual disease, multi-cancer early detection, clonal haematopoiesis, evidence translation, clinical utility","lastPublishedDoi":"10.21203/rs.3.rs-9635682/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9635682/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground. \u003c/strong\u003eDespite more than two decades of translational research, the clinical implementation of cell-free DNA (cfDNA)–based assays remains uneven, with a well-established role in prenatal aneuploidy screening contrasting sharply with the largely investigational status of multi-cancer early detection (MCED). Existing reviews have catalogued the breadth of cfDNA applications, but none has systematically appraised where each application stands on the evidence-to-practice continuum or why promising assay performance does not automatically translate into clinical utility.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods. \u003c/strong\u003eWe conducted a scoping narrative review in accordance with PRISMA-ScR 2018 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched for articles published between January 2015 and April 2025. After duplicate removal and screening, 70 peer-reviewed articles were included. We applied a five-dimension Evidence Translation Framework (ETF) to categorise each application by analytical readiness, clinical validation depth, regulatory status, implementation feasibility, and health-economic evidence.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults. \u003c/strong\u003eNon-invasive prenatal testing (NIPT) and select companion diagnostic assays for circulating tumour DNA (ctDNA) are the only cfDNA applications meeting all five ETF criteria. ctDNA-guided minimal residual disease (MRD) monitoring in colorectal and breast cancer, and donor-derived cfDNA for kidney allograft surveillance, are approaching clinical readiness but require larger prospective trials. MCED tests, despite high specificity (\u0026gt; 99%), carry positive predictive values below 10% in low-prevalence screening populations — a mathematical consequence of disease prevalence rather than assay failure alone. Analytical confounders, particularly clonal haematopoiesis of indeterminate potential (CHIP), remain under-addressed in clinical cfDNA pipelines.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions. \u003c/strong\u003eThe ETF proposed here provides a structured, reproducible instrument for matching cfDNA assays to their appropriate clinical role. Rather than viewing cfDNA as a monolithic technology approaching universal adoption, clinicians and policymakers should engage with each application on its own evidentiary merits. Priority areas for investment include CHIP-subtraction algorithms, standardised preanalytical protocols, and risk-stratified screening trial designs with mortality endpoints.\u003c/p\u003e","manuscriptTitle":"Navigating the Translation Gap in Cell-Free DNA Diagnostics: A Critical Evidence Framework Across Oncology, Prenatal Medicine, and Transplant Surveillance","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-05-08 04:20:33","doi":"10.21203/rs.3.rs-9635682/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"730b00b9-9627-422e-9309-99555d9f799c","owner":[],"postedDate":"May 8th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":67670675,"name":"Oncology"},{"id":67670676,"name":"Molecular Biology"}],"tags":[],"updatedAt":"2026-05-08T04:20:33+00:00","versionOfRecord":[],"versionCreatedAt":"2026-05-08 04:20:33","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9635682","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9635682","identity":"rs-9635682","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}